Compare iShares China Large-Cap ETF (FXI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares China Large-Cap ETF trades at $34.27 (market cap $3.86B), while Regeneron Pharmaceuticals Inc trades at $746.12 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 19.7× iShares China Large-Cap ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FXI | REGN | |
|---|---|---|
Market Cap | $3.86B | $76.14B |
Volume | 16,323,837 | 500,239 |
52-Week High | $41.08 | $852.03 |
52-Week Low | $31.59 | $557.73 |
Typical Hold Time | 150 Days | 107 Days |
Sector | — | Health |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.19, up 2.3% today, but technical indicators show a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent U.S.-China diplomatic engagement offers potential for reduced trade tensions, but momentum remains weak with the ETF trading near key support at $33.
FXI presents a value opportunity trading at half the S&P 500's P/E ratio with a 1.98% yield, but requires tolerance for significant geopolitical risk. The ETF's heavy financial sector exposure and China's export-driven economy face protectionism threats, making it suitable only for diversified portfolios with high risk tolerance.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
